Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. CME/CE
  4. Comprehensive Care and Medical Management of Acromegaly: Achieving an Earlier Diagnosis and Biochemical Control

Comprehensive Care and Medical Management of Acromegaly: Achieving an Earlier Diagnosis and Biochemical Control

Understanding Trial Data

MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Comments
  • Overview

    Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.  

    Host: 
    Susan Samson, MD, PhD, FRCPC, FACE  
    Senior Associate Consultant 
    Department of Medicine, Diabetes,  
    Endocrinology and Metabolism  
    Neurologic Surgery Brain Tumor Program  
    Mayo Clinic 
    Jacksonville, FL 

    No relevant relationships reported 

    Faculty:  
    Eliza Geer, MD 
    Medical Director 
    Multidisciplinary Pituitary and Skull Base Tumor Center 
    Memorial Sloan Kettering Cancer Center 
    New York, NY  

    Dr. Geer has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Consulting Fees: Amryt/Chiesi, Crinetics, Recordati 
    Research: Ionis, Amryt/Chiesi, Recordati  

    Kevin Yuen, MD 
    Dignity Health Medical Group  
    Medical Director, Pituitary Program  
    Barrow Neurological Institute  
    Phoenix, AZ  

    Dr. Yuen has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Consulting Fees: Amryt/Chiesi, Ascendis, Crinetics, Ipsen, Neurocrine, Novo Nordisk, Recordati, Xeris 
    Research: Amryt/Chiesi, Ascendis, Corcept, Sparrow 

    Reviewers/Content Planners/Authors: 

    • Stephen Chavez has nothing to disclose. 
    • Cindy Davidson has nothing to disclose.  
    • Libby Lurwick has nothing to disclose. 
    • Tim Person has nothing to disclose.  
    • Colleen Resnick has nothing to disclose. 
    • Mara Siegel has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Recognize the constellation of symptoms related to acromegaly and the need for timely referral of patients with these symptoms to an endocrinologist  
    • Describe the biochemical, imaging, and visual field tests used to diagnose acromegaly, including type and location of tumor 
    • Apply knowledge from recent clinical trials, current guidelines, and best practices to patient selection for a second-generation somatostatin receptor ligand (SRL) agent for treatment of acromegaly  
    • Formulate evidence-based strategies for monitoring and managing treatment-related adverse events associated with a second-generation SRL agent
  • Target Audience

    This activity is designed to meet the educational needs of endocrinologists, primary care physicians, dentists, orthopedists, pituitary neurologists, internal medicine specialists, nurse practitioners, and physician associates.   

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.  

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0
    AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until January 25, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.  

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.   

  • Commercial Support

    This activity is supported by an independent educational grant from Recordati Rare Diseases.  

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

    Reproduction Prohibited 
    Reproduction of this materialis not permitted without written permission from the copyright owner. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule5 Oct 2024